AB-005
# AB-005

AB-005 or [1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 $(K_i$ = 5.5 nM) and CB2 receptors $(K_i$ = 0.48 nM). AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of UR-144 and XLR-11 as well as the (1-methyl-2-piperidinyl)methyl substituent of AM-1248 and AM-1220. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.

## Legal status

In 2013, psychoactive products in New Zealand containing this drug were given interim approval under psychoactive substances legislation.

